比较不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果  

Comparative application results in patients with advanced non-small cell lung cancer in different platinum-containing regimen

作　　者：马耀先 王绍义 

机构地区：[1]河南省许昌市中心医院肿瘤科,461000 [2]许昌市中级人民法院技术处

出　　处：《中国实用医刊》2015年第10期41-43,共3页Chinese Journal of Practical Medicine

摘　　要：目的 探讨不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果.方法 选择2011年3月至2012年9月许昌市中心医院收治的非小细胞肺癌的初治患者220例,根据化疗方案的不同分为紫杉醇组、吉西他滨组和多西他赛组.分别对其疗效及不良反应进行评价.结果 三组患者采用不同的治疗方案治疗后的ORR以及DCR比较差异均未见统计学意义（P＞0.05）.随访至2014年4月,有107例患者由于随访后期未定期进行影像学检查导致无法对疾病进展情况进行有效评估,余113例评定无进展生存期发现,吉西他滨组的无进展生存期最优,紫杉醇组次之,多西他赛组相对较差;紫杉醇组神经毒性明显重于多西他赛组,吉西他滨组最小,差异有统计学意义（P＜0.05）.结论 三种不同含铂治疗方案治疗晚期非小细胞肺癌均具有较好的疗效,但相比而言,紫杉醇与吉西他滨方案更能够延缓病情进展,近期疗效曼佳,而吉西他滨的安全性更好.Objective To investigate the effect of different applications on advanced platinumcontaining regimen in patients with non-small cells lung cancer.Methods Two hundred and twenty patients with non-small cell lung cancer were retrospectively selected from March 2011 to September 2012 in the Central Hospital of Xuchang,according to different chemotherapy,all the patients were divided into paclitaxel,gemcitabine and docetaxel group.The efficacy and adverse reactions were evaluated.Results The sex,age,pathological type,stage and the classification of the platinum agent of the three groups of patients were compared,there was no statistically significant difference （P 〉 0.05）.Three groups of patients with different treatment regimen,there were no statistically significant difference in ORR or DCR （P 〉 0.05）.Followed up to April 2014,107 patients unable to be evaluated due to late follow-up without imaging examination on a regular basis,an effective evaluation of the progress of the disease,the progression-free survival,in gemcitabine group was optimal,taxol group took second place,docetaxel group was relatively poor.The neurotoxicity of taxol group was significantly heavier than that of docetaxel group,gemcitabine group neurotoxicity was minimum.The difference were statistically significant （P 〈 0.05）.Conclusions Three different platinum-based treatment of advanced non-small cell lung cancer treatment has good effect,but paclitaxel and gemcitabine program is able to slow down the disease progression,the short-term curative effect is better,and the security of gemcitabine is better.

关 键 词：非小细胞肺癌 化疗 铂剂 

分 类 号：R734.2[医药卫生—肿瘤]